Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
(Aliso Viejo, CA) September 15, 2021 – Konica Minolta Precision Medicine (KMPM), a majority-owned subsidiary of Konica Minolta, Inc., announced today that it has changed its name to REALM IDx, Inc. The name change reflects the company’s focus in integrated diagnostics, an advanced field of clinical science that brings together genomics, radiology, pathology, and artificial intelligence to derive actionable insights that can empower healthcare providers to predict, diagnose, and treat disease. “We’re excited to announce the name change” said Dr. Aaron Elliott, Chief Executive Officer of REALM IDx, Inc.. “Our new name reflects not only our focus on advancing integrated diagnostics, but also the coming together of the rich multi-modal data generated by our subsidiary companies – genomics from Ambry Genetics, and radiology and pathology from Invicro. Combined with our proprietary software platforms, this integrated approach opens a new world of diagnostic insights that supports our mission to advance patient care.”
REALM IDx, Inc. is a healthcare company that is pioneering the field of Integrated Diagnostics (IDx), a new frontier of advanced clinical science that brings together laboratory medicine, radiology, pathology, and sophisticated artificial intelligence to derive actionable insights that predict, diagnose, and treat disease. Powered by proprietary software platforms, best-in-class genomics technology from Ambry Genetics Corporation, and industry-leading radiology and pathology services from Invicro, LLC, the company is uniquely equipped to collect, analyze, and report on multi-modal precision diagnostic data sets. REALM’s extensive network of healthcare providers and pharmaceutical partners will drive clinical access to innovations that lead to better medical solutions for patient care. To learn more, visit REALMIDx.com.
Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Contacts
For Ambry Genetics
gwen@gwengordonpr.com